We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

66 hedge funds and large institutions have $6.6M invested in Protalix BioTherapeutics in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 12 increasing their positions, 16 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,400% more call options, than puts

Call options by funds: $125K | Put options by funds: $5K

17% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 23

5% more funds holding

Funds holding: 63 → 66 (+3)

5.16% less ownership

Funds ownership: 12.85% → 7.69% (-5.2%)

25% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 16

45% less capital invested

Capital invested by funds: $11.9M → $6.6M (-$5.32M)

Holders
66
Holders Change
+3
Holders Change %
+4.76%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
12
Reduced
16
Closed
23
Calls
$125K
Puts
$5K
Net Calls
+$120K
Net Calls Change
+$75K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$946K
2
Goldman Sachs
Goldman Sachs
New York
+$437K
3
Jane Street
Jane Street
New York
+$309K
4
YIH
Y-Intercept (HK)
Hong Kong
+$187K
5
CC
Centiva Capital
New York
+$154K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.52M
2
State Street
State Street
Massachusetts
-$1.04M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$950K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$416K
5
N
Nuveen
North Carolina
-$342K
Name Holding Trade Value Shares
Change 		Change in
Stake
Mirae Asset Global ETFs Holdings
26
Mirae Asset Global ETFs Holdings
Hong Kong
$40K +$40.4K +34,167 New
Franklin Resources
27
Franklin Resources
California
$39.7K +$406 +344 +1%
CSS
28
Cubist Systematic Strategies
Connecticut
$37.5K +$37.8K +32,031 New
SSA
29
Schonfeld Strategic Advisors
New York
$32.6K +$33K +27,900 New
CPA
30
Capital Performance Advisors
California
$31.3K +$632 +535 +2%
ACA
31
Aptus Capital Advisors
Alabama
$24.5K +$1.54K +1,304 +7%
EI
32
Ethic Inc
New York
$23.4K +$23.7K +20,039 New
Citadel Advisors
33
Citadel Advisors
Florida
$21.6K -$22.8K -19,320 -51%
TRCT
34
Tower Research Capital (TRC)
New York
$20.9K +$16.5K +13,986 +359%
RhumbLine Advisers
35
RhumbLine Advisers
Massachusetts
$20.7K -$69.4K -58,789 -77%
KAS
36
Kestra Advisory Services
Texas
$18.7K – – –
Lido Advisors
37
Lido Advisors
California
$18.2K – – –
FI
38
Finivi Inc
Massachusetts
$17K – – –
JF
39
Jump Financial
Illinois
$16.6K +$16.8K +14,224 New
Balyasny Asset Management
40
Balyasny Asset Management
Illinois
$15.6K +$15.7K +13,299 New
AS
41
Altshuler Shaham
Israel
$14.2K – – –
SC
42
Savant Capital
Illinois
$14K +$14.2K +11,996 New
CFP
43
Cascade Financial Partners
California
$13K +$13.1K +11,100 New
EI
44
Ellevest Inc
New York
$12.3K +$12.4K +10,494 New
CFM
45
Catalyst Funds Management
Australia
$11.9K +$12K +10,200 New
HIM
46
Harbour Investment Management
Washington
$11.8K – – –
Fidelity Investments
47
Fidelity Investments
Massachusetts
$7.95K +$5.04K +4,265 +169%
National Bank of Canada
48
National Bank of Canada
Quebec, Canada
$6.95K – – –
TWC
49
TD Waterhouse Canada
Ontario, Canada
$6.84K – – –
Macquarie Group
50
Macquarie Group
Australia
$4.05K +$4.09K +3,460 New
1
2
3 4

PLX Hedge Fund Activity: Q2 2024 in Review

66 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q2 2024, worth a combined $6.6M — down 45% from $11.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new PLX positions and 23 closed out — a net gain of 4 holders — while 12 added to existing stakes and 16 trimmed.

The largest buyer was Millennium Management, adding an estimated $946K. The largest seller was BlackRock, cutting an estimated $3.52M.

  • 66 institutional investors held Protalix BioTherapeutics (PLX) as of Q2 2024, up from 63 in Q1 2024.
  • Funds reported $6.6M of Protalix BioTherapeutics stock for Q2 2024, down 45% quarter-over-quarter.
  • 27 funds opened new Protalix BioTherapeutics positions in Q2 2024 and 23 closed out, a net change of +4 holders.
  • The largest Protalix BioTherapeutics buyer in Q2 2024 was Millennium Management, an estimated $946K added.
  • The largest Protalix BioTherapeutics seller in Q2 2024 was BlackRock, an estimated $3.52M sold.

Based on aggregated 13F filings for Q2 2024.